Introduction {#sec1}
============

Germline mutations in *BRCA1* or *BRCA2* genes confer a significantly increased lifetime risk of developing breast cancer (BC), estimated at up to 6 times that of the average risk population \[[@bib1]\]. Healthy women who carry a deleterious mutation in *BRCA1*/*2* are counseled about BC risk-management options including a tight surveillance scheme from 25 to 30 years of age, chemoprevention, and risk-reducing surgeries \[[@bib2]\]. While admittedly bilateral risk reducing mastectomy (BRRM) is the most effective method for actively reducing BC risk among *BRCA1/2* mutation carriers \[[@bib3],[@bib4]\], rates of *BRCA1/2* carriers who opt for this option are below 50% in most countries \[[@bib5], [@bib6], [@bib7], [@bib8]\]. Data regarding survival benefits of BRRM over intensive surveillance are conflicting, primarily due to the lack of prospective trials \[[@bib9]\]. The American Cancer Society recommendations for surveillance of female *BRCA1/2* mutation carriers from 2007 included magnetic resonance imaging (MRI) of the breast and annual mammography \[[@bib10]\]. Annual MRI screening has been shown to be the most sensitive screening tool for high-risk women and associated with a significant reduction in the incidence of advanced-stage BC in *BRCA1/2* mutation carriers \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\]. Based on these findings, population screening for *BRCA1/2* mutations, at least for populations exhibiting founder mutations was suggested \[[@bib16], [@bib17], [@bib18], [@bib19]\], to facilitate early detection in young mutation carriers who may not be aware of their risk. However, to what extent such early detection in female *BRCA1/2* carriers who adhere to the recommended early detection scheme affects oncological treatment decisions has sparsely been reported \[[@bib9],[@bib20]\].

The purpose of the present study was to assess stage at diagnosis and therapeutic approaches in Israeli *BRCA1/2* mutation carriers and compare these parameters in women who developed BC while adhering to the recommended surveillance scheme ("known carriers"), with BC cases who became aware of their *BRCA* mutation status after BC diagnosis ("latent carriers"). Noteworthy, the Israeli population has the highest prevalence of *BRCA1/2* mutation carriers, when most of the mutations are limited to one of the 3 founder Ashkenazi Jewish mutations \[[@bib21]\]. Yet, the rate of uptake of BRRM among *BRCA1/2* mutation carriers is less than 20% \[[@bib8]\]. No studies have been done so far to explain these low rates, or whether these rates have changed in Israel over time.

Methods {#sec2}
=======

Retrospective data were collected on female *BRCA1/2* mutation carriers treated for BC at the Chaim Sheba Medical Center, including both the Oncology Institute and the Meirav Center for Breast Health's high-risk clinic.

Since 2007, the surveillance scheme for asymptomatic *BRCA1* and *BRCA2* mutation carriers in our center follows mostly the ACS \[[@bib10]\] and NCCN guidelines \[[@bib2]\]. All mutation carriers undergo biannual clinical breast examination from the age of 25, annual breast MRI starting at age 25 years, alternating with annual mammography and sonography starting at age 35 years. Self-developed guidelines also include clinical breast examination and sonography every 3 months in pregnant and breastfeeding *BRCA1/2* mutation carriers. These surveillance guidelines and systemic BC treatment protocols for early stage disease have not changed in our center since 2007.

The Meirav Center high-risk clinic offers all *BRCA1* and *BRCA2* mutation carriers the early detection scheme outlined above. All registered *BRCA1*/*BRCA2* mutation carriers attending the high-risk clinic who were diagnosed with breast cancer were included in the study. Carriers who underwent BRRM and cancer free carriers as of June 2019 were excluded from the study. None of the known mutation carriers was treated with chemo-preventive agents. All adhered to the recommended screening scheme.

The latent carriers were identified during oncological treatment and follow-up at the Oncology Institute. These patients started follow-up at the Meirav Center high-risk clinic only after completing their oncological treatment. There were no data available on the rate of adherence to the population recommended screening (in Israel starting at age 50 in general population, and recommended from age 40 for women with first-degree relatives with BC) among latent carriers.

Data were reviewed from January 2007 to May 2019. For latent mutation carriers in whom BC was diagnosed prior to 2007 (19%), the date of first diagnosis was referred as the start of follow-up period. The main variables evaluated were tumor characteristics, age and stage at diagnosis, and therapeutic approaches.

Relevant demographic and clinical features were compared between known and latent carriers or between *BRCA1*-and *BRCA2*-mutation carriers by using the student t-test and the chi-square test, as appropriate. Analyses were conducted using SPSS version 25 (SPSS, Inc).

The study was approved by the ethics committee of the Chaim Sheba Medical Center, and given its retrospective nature and lack of direct patient contact, was exempt from obtaining patients written informed consent. Notably, all patients consented for the initial *BRCA* testing and data acquisition as part of the Oncogenetics counseling process.

Results {#sec3}
=======

Overall, relevant clinical information was available for 298 *BRCA1/2* associated BC cases. Median follow-up time from BC diagnosis was 77.4 months (range, 3.5--520). All known carriers were diagnosed with BC after January 2007. Among latent carriers, 163/202 (81%) were diagnosed after January 2007.

*Clinical characteristics* - Known carriers included 96 women (median age at diagnosis 44.7 years \[range 27.8--80.3 years\]), 71 (74%) were *BRCA1* mutation carriers, 23 (24%) *BRCA2* mutation carriers, and two (2.1%) carried mutations in both genes. Latent carriers included 202 women (median age at diagnosis 43.7 years (range 23.8--75 years), p = 0.8284. Of latent carriers 118 (58%) were *BRCA1* mutation carriers and 84 (42%) harbored a *BRCA2* mutation. Additional relevant clinical data are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1Clinical data of known vs latent *BRCA1/2* mutation carriers.Table 1AllKnown carriersLatent carriersP-valueNumber of pts29796202Median follow-up, months (range)47.9 (3.7--141)81.3 (3--491)Median age at diagnosis, months (range)44.7 (27.8--80.3)43.7 (23.8--75)0.828*BRCA1* carriers age at diagnosis, mean (SD) [a](#tbl1fna){ref-type="table-fn"}43.6 (11.24)44.0 (11.1)0.81*BRCA2* carriers age at diagnosis, mean (SD)49.8 (13.85)47 (9.46)0.26**Mutation in**, No. (%) ***BRCA1*71 (74)118 (58)**0.0076 185delAG39 (55)69 (58.5) 5382insC12 (17)21 (17.8) Other4 (5.6)14 (11.9) Not specified16 (22.5)14 (11.9) ***BRCA2*23 (24)84 (42)**0.0026 *6174delT*18 (78)66 (78.6) *8765delAG*2 (9)4 (4.8) Other012 (14.3) Not specified3 (13)2 (2.3) ***Both*2 (2)**0Performed BSO, No. (%)\
(*% of them prior to BC diagnosis*)68 (71)\
*66.2*173 (85.6)\
*2*0.0028**First diagnosed by**, No. (%) MRI56 (58.3)5 (2.5)\<0.00001 Mammography17 (17.7)43 (21.3)0. 4697 US9 (9.4)9 (4.5)0.0986 Self-Palpation [b](#tbl1fnb){ref-type="table-fn"}14 (14.6)131 (64.9)\<0.00001 Unknown014 (6.9)0.0085Diagnosed during pregnancy or postpartum, No. (%)9 (9.4)18 (8.9)0.8884**Recurrent disease**, No. (%) Ipsilateral recurrence2 (2.1)23 (11.4)0.0069 Contralateral second primary4 (4.2)33 (16.3)0.0031 Distant recurrence3 (3.1)20 (9.9)0.0401 Non-BC after BC diagnosis0[c](#tbl1fnc){ref-type="table-fn"}8 (4)[d](#tbl1fnd){ref-type="table-fn"}0.0473**Status at last follow-up**, No. (%) Alive without disease93 (95.8)178 (88.1)0.0338 Alive with disease016[e](#tbl1fne){ref-type="table-fn"} (7.9)\<0.00001 Deceased3 (3.1)8[f](#tbl1fnf){ref-type="table-fn"} (4)0.7014[^2][^3][^4][^5][^6][^7][^8]

*Tumor features* - Of known carriers, 19/96 (19.8%) were diagnosed with ductal carcinoma in situ (DCIS) vs. 10/202 (5%) in the group of latent carriers (p = 0.0001). Stage T1N0 disease was diagnosed in 54/96 (56.3%) of known carriers vs. 57/202 (28.2%) of latent carriers (p \< 0.00001). Node-positive disease was diagnosed in 11/96 (11.5%) of known carriers vs. 98/202 (48.5%) of latent carriers (p \< 0.00001). Metastatic disease was diagnosed at presentation in none of the known carriers vs. 4/202 (2%) of latent carriers (p = 0.1637). Tumor characteristics in each group and separately for *BRCA1* and *BRCA2* mutation carriers are summarized in [Table 2](#tbl2){ref-type="table"}.Table 2Tumor characteristics in known vs latent *BRCA1/2* mutation carriers.Table 2Known carriers N = 96Latent carriers N = 202*BRCA1BRCA2*P-value*BRCA1BRCA2*P-value**Number of patients (%)**73 (**76**)[a](#tbl2fna){ref-type="table-fn"}23 (**24**)117 (**58**)85 (**42**)**Stage at diagnosisDCIS,** No. (**%**)14/73 (**19**.**2**)[a](#tbl2fna){ref-type="table-fn"}5/23 (**21.7**)NS3/117 (**2.6**)7/85 (**8.2**)NS**T1N0**, No. (**%**)41/73 (**56.2**)13/23 (**56.5**)NS34/117 (**29**)23/85 (**27**)NS T1aN010/41 (24)1/13 (7.7)NS1/34 (2.9)1/23 (4.3)NS T1bN016/41 (39)6/13 (46.15)NS3/34 (8.8)2/23 (8.7)NS T1cN015/41 (37)6/13 (46.15)NS21/34 (61.8)15/23 (65)NS T1(unknown)N0009/34 (26.5)5/23 (22)NS**T2-3N0**, No. (%)11/73 (**15**)1/23 (**4.3**)NS19/117 (**16.3**)13/117 (**11**)**Node-positive disease**, No. (**%**)7/73 (**9.6**)4/23 (**17.4**)NS60/117 (**51.3**)38/85 (**44.7**)NSBilateral disease, No. (%)4/73 (**5.5**)[c](#tbl2fnc){ref-type="table-fn"}03/117 (**2.6**)2/85 (**2.4**)[d](#tbl2fnd){ref-type="table-fn"}NSMetastatic at presentation, No. (%)0004NS**Invasive disease cases**[b](#tbl2fnb){ref-type="table-fn"}**60**[c](#tbl2fnc){ref-type="table-fn"}18**119**[d](#tbl2fnd){ref-type="table-fn"}**77** Triple-negative, No. (**%**)42/60 (**70**)3/18 (**17**)0.000284/119 (**70.6**)19/77 (**25**)0.0001 ER-positive Her2-negative**,** No. (**%**)14/60 (**23**)14/18 (**78**)0.000127/119 (**22.7**)48/77 (**62**)0.0001 Her2-positive, No. (**%**)4/60 (**7**)1/18 (**5**)NS8/119 (**6.7**)10/77 (**13**)NS[^9][^10][^11][^12][^13]

*Therapeutic decisions*- The treatment regimens for all participants are summarized in [Table 3](#tbl3){ref-type="table"}. Chemotherapy was recommended for 49/96 (51%) of the known carriers (including all BC stages), 46 of them (47.9%) received either neoadjuvant (n = 12) or adjuvant (n = 34) chemotherapy (74% of them for triple-negative disease). Three additional patients refused for the recommended chemotherapy, two of them with triple-negative T1bN0 disease and one with triple-negative T1cN0 disease. Among the 46 patients receiving chemotherapy, 38 (83%) were *BRCA1* mutation carriers, and 8 (17%) were *BRCA2* mutation carriers. Among the 73 known *BRCA1* mutation carriers, 38 (52%) received chemotherapy compared with 8/23 (35%) of the known *BRCA2* mutation carriers. Patients with invasive disease for whom chemotherapy was not recommended (n = 28) had triple-negative T1aN0 disease (n = 8) or low-risk stage I ER-positive disease (n = 20). Six of the 28 patients with invasive ER-positive/Her2-negative disease in this group had OncotypeDx testing - 3 of them had recurrence scores (RS) between 18 and 20, one had RS = 26 (was not recommended chemotherapy in 2014), two had high RS (35, 42) and received chemotherapy. Radiotherapy was given to 41/96 (42.7%) of known carriers, 30 (73%) following lumpectomy without nodal involvement, 2 (5%) post-lumpectomy with regional nodal irradiation, and additional 9 (22%) had postmastectomy irradiation due to nodal involvement (n = 8) or T3N0 disease (n = 1).Table 3Treatments delivered in known vs latent *BRCA1/2* mutation carriers.Table 3Known carriers\
N = 96Latent carriers\
N = 202*BRCA1BRCA2*P-value*BRCA1BRCA2*P-value**Number of patients (%)**73 (**76**)[a](#tbl3fna){ref-type="table-fn"}23 (**24**)118 (**58**)84 (**42**)**Chemotherapy**, No. (**%**)**46 (48)162 (80)**\<0.00001**Overall**38/73 (**52**)8/23 (**35**)0.227699/118 (**84**)63/84 (**75**)0.166 Adjuvant29/38 (76)5/8 (63)52/99 (52.5)36/63 (57) Neoadjuvant9/38 (24)3/8 (37)47/99 (47.5)27/63 (43) Refused recommended treatment [b](#tbl3fnb){ref-type="table-fn"}3020**Chemotherapy by tumor types** Triple-negative disease31/38 (**81.6**)3/8 (**37.5**)0.032578/99 (**79**)19/63 (**30**)0.0057 ER-positive Her2-negative3/38 (**7.9**)4/8 (**50**)0.013413/99 (**13**)34/63 (**54**)0.0001 Her2-positive4/38 (**10.5**)1/8 (**12.5**)0.87058/99 (**8**)10/63 (**16**)0.1998**Surgery**, No. (%) Lumpectomy only21/73 (28.2)13/23 (56.5)0.029550/118 (42.4)46/84 (54.8)0.1167 Unilateral Mastectomy1/73 (1.4)1/23 (4.3)0.972210/118 (8.5)10/84 (11.9)0.5717 Synchronous bilateral mastectomy as primary surgery36/73 (49.3)8/23 (34.8)0.327226/118 (22)10/84 (11.9)0.0954 Metachronous bilateral mastectomy following lumpectomy15/73 (20.5)1/23 (4.3)0.134432/118 (27.1)14/84 (16.7)0.1151No surgery4[c](#tbl3fnc){ref-type="table-fn"}**Radiotherapy,** No. (**%**)**41 (42.7)168 (83.2)**\<0.00001**Overall**27/73 (**37**)14/23 (**61**)96/118 (**81.4**)73/84 (**87**) Post-lumpectomy, node-negative disease20/27 (74)10/14 (71)0.856134/96 (35)31/71 (44)0.3576 Post-lumpectomy with regional nodal radiation1/27 (4)1/14 (7)0.627836/96 (37.5)23/71 (32)0.604 Postmastectomy radiation6/27 (22)3/14 (21)0.953627/96 (28)17/71 (24)0.66811[^14][^15][^16][^17]

Of latent carriers, 162/202 (80.2%) received either neoadjuvant (n = 74) or adjuvant (n = 88) chemotherapy (p \< 0.00001), 59.3% of them for triple-negative disease, 61% of them with *BRCA1* mutation. Twelve of the 75 patients with invasive ER-positive/Her2-negative disease in this group underwent OncotypeDx testing - 9 of them had RS between 9 and 24, additional 3 patients had high RS (32, 35, 41) and received chemotherapy. Radiotherapy was delivered to 168/202 (83.2%) of latent carriers, 65 (38.7%) of them following lumpectomy without nodal involvement, 59 (35.1%) of them post-lumpectomy with regional nodal irradiation, and additional 44 (26.2%) had postmastectomy irradiation due to nodal involvement (n = 36) or T2-3N0 disease (n = 6) and additional two for T1N0 disease (unspecified reasons).

*Risk reducing surgeries* - BRRM was performed on 60/96 (62.5%) of the known carriers, 73% of them at the time of primary tumor resection and the rest -- at a later stage. Among latent carriers, 82/202 (40.6%) underwent BRRM, 44% at the time of primary tumor resection (p \< 0.001).

*Recurrent disease* -- as shown in [Table 1](#tbl1){ref-type="table"}, despite early diagnosis and recommended oncological treatment, 3/96 (3.1%) of the known carriers had metastatic recurrence between 20 and 44 months of initial diagnosis and died of BC. All three were *BRCA1* mutation carriers and received adjuvant chemotherapy - one for T2N0 triple-negative tumor, one for T1cN0 ER-positive disease (with Oncotype Dx recurrence score of 38), and one for T2N1 ER-positive lobular carcinoma. Among latent carriers, 20 women (10%) had distant BC recurrence, of whom 15 (75%) remain alive with disease and 5 deceased.

Discussion {#sec4}
==========

In the present study, in line with previously reported studies \[[@bib12],[@bib14],[@bib15]\], diagnosis of early stage disease (DCIS or T1N0) was significantly more prevalent in the group of known *BRCA1/2* mutation carriers adhering to the recommended tight surveillance scheme that stresses the importance of bi-annual breast imaging -- MRI alternating with mammography \[[@bib2],[@bib10]\]. Therefore, our findings further support the previously suggested population screening for *BRCA1/2* mutations, at least for founder mutations, where these exist \[[@bib16], [@bib17], [@bib18]\]. It should be noted that interval cancers were not infrequent (14.6%) among known carriers, 12/14 of them with *BRCA1* mutation. Biannual MRI screening has been recently suggested as more beneficial screening strategy, especially for *BRCA1* mutation carriers \[[@bib23]\], but this is still not considered as standard of care. There are no data on the rate of adherence of any of the latent carriers to the population recommended BC screening (starting at age 50 in Israel). As has previously been reported \[[@bib16],[@bib17]\], in nearly 50% of Jewish *BRCA* mutation carriers there is no family history suggestive of inherited predisposition. Thus, it seems likely that 50% of the latent carriers in our study who are under age 50 were not screened prior to being diagnosed with breast cancer. In addition, it seems plausible that if a significant proportion of "latent carriers" were enrolled in early detection programs (e.g. awareness programs) or tailored screening for higher-risk populations because of family history, a substantial proportion of screened tumors would have been diagnosed by imaging rather than by self-palpation. As shown in [Table 1](#tbl1){ref-type="table"}, almost 2/3 of the cancers in the latent carrier group were first discovered by self-palpation and not by screening. Taken together these considerations make a selection bias less likely.

Despite early stage BC diagnosis, almost 50%, of known carriers were treated with chemotherapy, with higher proportion of *BRCA1* mutation carriers, mostly because of higher prevalence of triple-negative tumors. In addition, 3% of those patients died of recurrent disease despite early stage BC diagnosis. These findings raise two important, clinically relevant questions. First, is there overtreatment of stage I triple-negative disease? Most international guidelines recommend "considering" adjuvant chemotherapy for triple-negative breast cancer (TNBC) at stage T1bN0 up to age 70 years, and recommend giving adjuvant chemotherapy for T1cN0 disease and lymph node positive disease \[[@bib24], [@bib25], [@bib26]\]. Unfortunately, at present there are no validated tools to predict which patients who fit these criteria can be adequately and successfully treated without chemotherapy. Previous studies suggested that TNBC can be molecularly dissected to different subtypes, each showing a distinct biological behavior \[[@bib27]\]. However, these tools have not attained widespread clinical use or have been prospectively validated as predictive tools to resolve this therapeutic dilemma. Although a 70-gene assay (MammaPrint™) was validated in a small cohort of TNBC to predict risk of distant recurrence \[[@bib28]\], this assay is not recommended for routine treatment decisions in TNBC \[[@bib29]\].

The second clinically relevant issue raised is to what extent this information could impact the specific healthy *BRCA1/2* mutation carrier's decision on risk-reducing surgeries. Discussion with a *BRCA1/2* mutation carrier regarding surveillance and risk-reducing options depends on the specific clinical scenario and age of the mutation carrier. For a healthy 30-year-old *BRCA1* carrier, BRRM is an attractive option for active BC risk reduction. While the data regarding survival benefit of BRRM over intensive surveillance have been conflicting so far, recent analysis of the Dutch large multicenter cohort study showed that BRRM was associated with lower mortality then surveillance during a mean follow-up of 10.3 years, mostly for *BRCA1* mutation carriers \[[@bib9]\]. In that study the data presented (but not discussed) show that 62% of the *BRCA1* mutation carriers and 39% of the *BRCA2* mutation carriers in the Dutch series were treated with chemotherapy, in line with the data presented herein. Chéreau et al. also reported high proportion of aggressive tumors requiring adjuvant chemotherapy in a small cohort (21 patients) of "known" mutation carriers undergoing intensive screening \[[@bib20]\]. However, 67% of carriers in that study were previously diagnosed with BC, unlike the present study, where all known carriers were newly diagnosed with BC in the course of adhering to the recommended follow-up scheme.

Currently, there is a limited ability to better define specific personal BC risk and the variable penetrance rates affected by factors such as mutation location, ethnicity, specific family history, modifier genes, environmental exposures and life style habits \[[@bib30]\]. Counseling for BRRM is very complex and delicate: it usually involves discussion of extent of cancer risk reduction/protection, risks associated with surgeries, and breast reconstructive options. It is also important to address the psychological and quality-of-life aspects of BRRM \[[@bib31]\]. It is plausible that BRRM decision making can sometimes be driven primarily by the desire to avoid cancer diagnosis and treatment even more than by any survival advantage \[[@bib32]\]. Therefore, it is crucial for asymptomatic mutation carriers, especially those harboring *BRCA1* mutations, to understand and be aware of the high rates of chemotherapy used even when early stage BC detection is indeed attained.

There are several inherent limitations to this study. This is a single institution study, with a limited number of participants and a very well-defined, narrow spectrum of *BRCA1/2* mutations. There also could be a selection bias in the known carriers' cohort, who could possibly become aware of their mutation status because of significant family history, and therefore were more motivated to follow the recommended surveillance scheme. There were also differences in the distribution of *BRCA1* vs *BRCA2* mutations in known compared with latent mutation carriers.

To the best of our knowledge, this is one of a few studies to assess the treatment approaches in an admittedly relatively small cohort of known *BRCA1/2* mutation carriers diagnosed with early stage BC who adhered to the recommended surveillance scheme. Obviously, more studies with larger numbers of mutation carriers of diverse ethnicities and longer follow up are needed to validate the data presented herein. If validated, the possibility of being treated with chemotherapy or radiotherapy should be discussed with every *BRCA1/2* carrier, especially *BRCA1* mutation carriers, since this may be an additional factor to influence a woman's decision to undergo BRRM.
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[^1]: Present address - Oncology Institute, Assuta Medical Center, Ramat Hahayal, Tel Aviv.

[^2]: Abbreviations: BC, Breast cancer; BSO, bilateral salpingo-oophorectomy; NS, non-significant.

[^3]: Including 2 carriers of both *BRCA1* and *BRCA2* mutations.

[^4]: Interval tumors in the "known carriers" cohort/tumors first discovered by the patient and not by population screening in the "latent carriers" cohort.

[^5]: Seven women had cancer prior to BC diagnosis: Ovarian cancer (n = 3), Uterine cervix cancer (n = 1), Gastric cancer (n = 1), Colon cancer (n = 1), Parotid gland Merkel cell tumor (n = 1).

[^6]: Pancreatic cancer (n = 1), Non-Hodgkin Lymphoma (n = 1), Ovarian cancer (n = 1), Rectal cancer (n = 1), Bladder cancer (n = 1), Chronic myelogenous leukemia (n = 1), Thyroid cancer (n = 1), Endometrial cancer (n = 1). Additional patient had Ovarian cancer prior to BC (performed genetic testing only after BC diagnosis).

[^7]: Including one patient with Ovarian cancer on treatment.

[^8]: Including three patients with non-BC related deaths.

[^9]: Abbreviations: DCIS, ductal carcinoma in situ; NS, non-significant.

[^10]: Including 2 carriers of both *BRCA1* and *BRCA2* mutations.

[^11]: Excluding DCIS.

[^12]: Four of 59 patients with invasive carcinomas had bilateral disease - 3 of them with both triple-negative tumors (calculated as single case) and 1 had triple-negative and ER-positive tumors (calculated as an additional case).

[^13]: Five of 115 patients with invasive carcinomas had bilateral disease -- 1 of them with both triple-negative tumors (calculated as single case), 3 of them with triple-negative and Her2-positive tumors and 1 had triple-negative and ER-positive tumors (each of these patients calculated as two cases). One additional patient had bilateral DCIS.

[^14]: Abbreviations: DCIS, ductal carcinoma in situ.

[^15]: Including 2 carriers of both *BRCA1* and *BRCA2* mutations.

[^16]: All patients had triple-negative disease, two of them with stage T1bN0 and one with stage T1cN0.

[^17]: Metastatic at presentation.
